Diabetes, Obesity & Metabolism最新文献_第10页

Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study. 代谢功能障碍相关的脂肪变性肝病和癌症风险：一项队列研究

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-09 DOI: 10.1111/dom.16186

Yu Peng, Peng Wang, Fubin Liu, Xixuan Wang, Changyu Si, Jianxiao Gong, Huijun Zhou, Jiale Gu, Ailing Qin, Weijie Song, Fangfang Song

{"title":"Metabolic dysfunction-associated steatotic liver disease and cancer risk: A cohort study.","authors":"Yu Peng, Peng Wang, Fubin Liu, Xixuan Wang, Changyu Si, Jianxiao Gong, Huijun Zhou, Jiale Gu, Ailing Qin, Weijie Song, Fangfang Song","doi":"10.1111/dom.16186","DOIUrl":"https://doi.org/10.1111/dom.16186","url":null,"abstract":"Background: Fatty liver disease may be associated with increased risks of intrahepatic and extrahepatic cancers. Our objective was to investigate associations between new subcategories of steatotic liver disease (SLD) recently proposed by nomenclature consensus group and cancer risk.Methods: A total of 283 238 participants from the UK Biobank were included. Based on information on cardiometabolic factors, alcohol consumption and the specific aetiology of SLD, individuals were categorized into four groups: no SLD (n = 170 885), metabolic dysfunction-associated steatotic liver disease (MASLD, n = 74 510), MASLD with increased alcohol intake (MetALD, n = 23 320) and other SLD (n = 6718). Outcomes were overall incident cancer (n = 39 352) and 21 site-specific cancers. The Cox proportional hazards model was used to estimate relationships between subcategories of SLD and cardiometabolic factors in MASLD with cancer risk. Population attributable risk (PAR) of cancer associated with SLD was estimated.Results: MASLD was the most prevalent SLD in the general population. All SLD subcategories were associated with elevated risks of overall cancer, digestive system cancers (except gastric cancer) and breast cancer (HRs 1.079-4.663). Additionally, MASLD was associated with increased risks of renal cancer, endometrial cancer and Hodgkin lymphoma. Compared to MetALD and other SLDs, MASLD has a higher PAR% for the majority of aforementioned cancers. This could be largely explained by its common metabolic abnormalities, dominantly characterized by overweight/obesity and elevated blood pressure, concomitant with hyperglycaemia and hyperlipidaemia.Conclusions: All subcategories of SLD, particularly MASLD with multiple metabolic abnormalities, were associated with increased risks of multiple cancers, providing a new perspective for cancer prevention.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941981","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Efficacy of myo-inositol and zinc on insulin resistance in a paediatric population with obesity. 肌醇和锌对儿童肥胖人群胰岛素抵抗的影响。

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-09 DOI: 10.1111/dom.16185

Valentina Antoniotti, Cristina Partenope, Arianna Solito, Valentina Mancioppi, Jessica Baima, Federico Medina, Sotirios Dimarakis, Alida Agostini, Maria T Sista, Alice Monzani, Lorenza Scotti, Ivana Rabbone, Flavia Prodam, Simonetta Bellone

{"title":"Efficacy of myo-inositol and zinc on insulin resistance in a paediatric population with obesity.","authors":"Valentina Antoniotti, Cristina Partenope, Arianna Solito, Valentina Mancioppi, Jessica Baima, Federico Medina, Sotirios Dimarakis, Alida Agostini, Maria T Sista, Alice Monzani, Lorenza Scotti, Ivana Rabbone, Flavia Prodam, Simonetta Bellone","doi":"10.1111/dom.16185","DOIUrl":"https://doi.org/10.1111/dom.16185","url":null,"abstract":"Aim: To assess the efficacy of the combined administration of myo-inositol and zinc, a mineral involved in the insulin pathway, in paediatric obesity with insulin resistance on HOMA-IR, glucose-insulin metabolism, and lipid profile.Materials and methods: Double-blind, randomized, placebo-controlled study conducted in North Italy. Fifty-six patients (10-18 years, Tanner stage ≥3) with obesity and insulin resistance were randomized to myo-inositol (2000 mg), zinc gluconate (5 mg), and galactooligosaccharides (GOS) from plant-based origin (1000 mg) (TRT) or placebo (PLC) containing only GOS from plant-based origin (1000 mg). All patients received an isocaloric diet following the Mediterranean diet style. Data were collected at baseline (V0) and after 3 months (V1). The primary outcome was the insulin resistance index (HOMA-IR).Results: Fifty out of 56 recruited subjects completed the study. TRT improved HDL cholesterol level compared to PLC (p = 0.05) but not insulin resistance. A stratified post hoc analysis was performed by sex, BMI, and subgroups of adherence to the Mediterranean diet. Subjects were divided for obesity grade, fasting insulin (p = 0.0137) and HOMA-IR (p = 0.0273) were lower in TRT than in PLC patients, with a greater effect on severe obesity. No adverse events were detected.Conclusion: Three months of supplementation with myo-inositol and zinc were beneficial on lipid profile and in managing obesity complications at least in subjects with severe phenotype. Thus, myo-inositol and zinc could be used as non-pharmacological agents. This work suggests a long-term study with a larger sample size to enrich the findings.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The influence of preoperative fat distribution on post-bariatric surgery body mass index and body weight loss. 术前脂肪分布对减肥手术后体重指数及体重减轻的影响。

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-09 DOI: 10.1111/dom.16172

Shi-Jing Lu, Yan-Yun Wang, Tao-Tao Zhang, Xiang-Wen Zhang, Si-Bo Liu, Xiu-Qin Miao, Guo-Hua Zhao, Yong Wang, Hai-Long Chen

{"title":"The influence of preoperative fat distribution on post-bariatric surgery body mass index and body weight loss.","authors":"Shi-Jing Lu, Yan-Yun Wang, Tao-Tao Zhang, Xiang-Wen Zhang, Si-Bo Liu, Xiu-Qin Miao, Guo-Hua Zhao, Yong Wang, Hai-Long Chen","doi":"10.1111/dom.16172","DOIUrl":"https://doi.org/10.1111/dom.16172","url":null,"abstract":"Background: The body weight following bariatric surgery is a primary concern for both healthcare professionals and surgical candidates. However, it remains unclear whether variations in preoperative fat distribution influence weight loss outcomes.Objective: The aim of this study was to evaluate the effect of abdominal fat distribution on postoperative weight loss and body mass index (BMI) reduction, and to clarify the role of different fat depots in weight loss outcomes.Methods: Preoperative data from patients with overweight or obesity, along with their weight records at 1, 2 and 5 years following surgery, were retrospectively collected. Multiple levels of abdominal fat areas were measured using computerized tomography imaging. Statistical analyses included Pearson's correlation coefficients, multiple linear regressions, ridge regressions, decision tree regressions and paired t tests to evaluate the associations and influences.Results: A total of 139 patients were initially included. The statistical analysis results indicated that umbilical subcutaneous adipose tissue (SAT) was an independent factor influencing weight and BMI loss at the 1-year follow-up (n = 67, p < 0.01). Furthermore, umbilical SAT demonstrated significant correlations with sustained BMI reduction over the long term.Conclusion: Umbilical SAT is a significant factor in postoperative weight and BMI loss. Patients with greater SAT may experience more substantial weight and BMI reductions following surgery, offering new insights into personalized weight loss strategies and alternative approaches for assisted weight loss.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial. canag列净在老年人中的心血管、肾脏和安全性结局：来自CANVAS项目和CREDENCE试验的综合分析

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-09 DOI: 10.1111/dom.16190

Amanda Siriwardana, Luke Buizen, Min Jun, Sradha Kotwal, Clare Arnott, Meg J Jardine, Adeera Levin, Hiddo J L Heerspink, David M Charytan, Carol Pollock, Vlado Perkovic, Brendon L Neuen

{"title":"Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial.","authors":"Amanda Siriwardana, Luke Buizen, Min Jun, Sradha Kotwal, Clare Arnott, Meg J Jardine, Adeera Levin, Hiddo J L Heerspink, David M Charytan, Carol Pollock, Vlado Perkovic, Brendon L Neuen","doi":"10.1111/dom.16190","DOIUrl":"https://doi.org/10.1111/dom.16190","url":null,"abstract":"Aim: SGLT2 inhibitors may be underused in older adults with type 2 diabetes due to concerns about safety and tolerability. This pooled analysis of the CANVAS Program and CREDENCE trial examined the efficacy and safety of canagliflozin according to age.Methods: Pooled individual participant data from the CANVAS Program (n = 10 142) and CREDENCE trial (n = 4401) were analysed by baseline age (<65 years, 65 to <75 years, and ≥75 years). A range of adjudicated clinical outcomes were assessed, including major adverse cardiovascular events and CKD progression, as well as safety outcomes. Cox proportional hazards models and Fine and Gray competing risk analysis were used.Results: Among the 14 543 participants, 7927 (54.5%) were <65 years, 5281 (36.3%) were 65 to <75 years and 1335 (9.2%) were ≥75 years. Older participants had higher rates of atherosclerotic cardiovascular disease and heart failure, longer diabetes duration and lower mean eGFR. Reductions in cardiovascular and kidney outcomes with canagliflozin were consistent across age categories (all p trend >0.10), although there was some evidence that effects on cardiovascular death and all-cause death were attenuated with older age (p trend = 0.02 and 0.03, respectively). Although the incidence of adverse events increased with age, effects of canagliflozin on safety outcomes including acute kidney injury, volume depletion, urinary tract infections and hypoglycaemia, were not modified by age (all p trend >0.10).Conclusions: In patients with varying degrees of kidney function, canagliflozin reduced cardiovascular and kidney outcomes, regardless of age, with no additional safety concerns identified in older patients.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes. TCF7L2 rs7903146对2型糖尿病患者临床表现及并发症风险的影响

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-08 DOI: 10.1111/dom.16193

Aleksander L Hansen, Mette K Andersen, Leonie M Engelhard, Charlotte Brøns, Torben Hansen, Jens S Nielsen, Peter Vestergaard, Kurt Højlund, Niels Jessen, Michael H Olsen, Reimar W Thomsen, Allan Vaag

{"title":"Impact of TCF7L2 rs7903146 on clinical presentation and risk of complications in patients with type 2 diabetes.","authors":"Aleksander L Hansen, Mette K Andersen, Leonie M Engelhard, Charlotte Brøns, Torben Hansen, Jens S Nielsen, Peter Vestergaard, Kurt Højlund, Niels Jessen, Michael H Olsen, Reimar W Thomsen, Allan Vaag","doi":"10.1111/dom.16193","DOIUrl":"https://doi.org/10.1111/dom.16193","url":null,"abstract":"Aims: TCF7L2 rs7903146 is the most impactful single genetic risk variant for type 2 diabetes. However, its role on disease progression, complications and mortality among people with type 2 diabetes at diagnosis remains unclear.Materials and methods: We assessed the per allele impact of the rs7903146 T-allele on clinical characteristics and complication risk in 9231 individuals with type 2 diabetes at diagnosis and over a 10-year follow-up period. Log-binomial and robust Poisson regression analyses were used to estimate prevalence ratios for clinical characteristics and macro- and microvascular complications at diabetes onset, while Cox regression was applied to estimate the risk of complications post-diagnosis. Analyses were adjusted for sex, calendar year at birth, age at enrollment and diabetes duration.Results: The per T-allele impact was associated with 0.6 kg/m2 (95% CI: 0.4, 0.8) lower BMI, 1.4 cm (95% CI: 1.0, 1.8) smaller waist circumference, 5.6% (95% CI: 4.2, 7.0) lower insulin secretion and 5.0% (95% CI: 3.3, 6.7) higher insulin sensitivity. Over 10 years, the per T-allele impact was associated with lower risks for major adverse cardiovascular events (0.87 [95% CI 0.79, 0.95]), myocardial infarction (0.82 [95% CI: 0.72, 0.93]) and heart failure (0.85 [95% CI 0.73, 1.00]), with no significant impact on microvascular complications.Conclusions: The TCF7L2 variant is associated with less obesity, lower insulin secretion and higher insulin action at diabetes onset, and decreased risk of cardiovascular events following type 2 diabetes onset.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Long-term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes. 2型糖尿病患者TIR改善的长期健康效益和经济回报

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-08 DOI: 10.1111/dom.16168

Khalid Alkhuzam, Piaopiao Li, Sumaya Abuloha, Qiaochu Xue, Lizheng Shi, Vivian Fonseca, Yongkang Zhang, Hui Shao

{"title":"Long-term health benefit and economic return of time in range (TIR) improvement in individuals with type 2 diabetes.","authors":"Khalid Alkhuzam, Piaopiao Li, Sumaya Abuloha, Qiaochu Xue, Lizheng Shi, Vivian Fonseca, Yongkang Zhang, Hui Shao","doi":"10.1111/dom.16168","DOIUrl":"https://doi.org/10.1111/dom.16168","url":null,"abstract":"Objective: Time in range (TIR) is an important metric to measure variability of blood glucose levels. The aim is to quantify the long-term health benefits and economic return associated with improved TIR for individuals with type 2 diabetes (T2D).Method: A Markov model with three states (T2D, T2D with cardiovascular disease (CVD) and death) estimated 20-year medical costs, quality-adjusted life-years (QALY) gained and CVD risk under four TIR scenarios: >85%, 71%-85%, 51%-70% and ≤50%. The T2D population was identified using the National Health and Nutrition Examination Survey, and model parameters were sourced from literature. Costs were estimated from a healthcare sector perspective and standardized to 2021 US dollars. Cost ceilings were determined using three willingness-to-pay (WTP) thresholds: $100 000/QALY, $50 000/QALY and $0/QALY (cost-saving).Results: Compared to TIR <50%, improving TIR to 51%-70% resulted in a 0.79 QALY increase and 4.91% CVD risk reduction; to 71%-85%, a 0.95 QALY increase and 6.24% CVD risk reduction; to >85%, a 1.18 QALY increase and 8.75% CVD risk reduction. To be cost-effective at $100 000/QALY, annual costs for TIR improvements from <50% to 51%-70%, 71%-85% and >85% should be <$1148, $4200 and $7252, respectively. To be cost-saving, these costs should be <$612, $2816 and $5021.Conclusion: Improving TIR yields significant health benefits. We calculated feasible medical cost allocations for TIR improvements, informing the implementation of interventions like continuous glucose monitoring devices.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis. 二甲双胍与2型糖尿病患者痴呆风险的关联：一项系统综述和荟萃分析

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-08 DOI: 10.1111/dom.16192

Chunbian Tang, Jiayi Hao, Fengran Tao, Qingguo Feng, Ying Song, Baoqi Zeng

{"title":"Association of Metformin use with risk of dementia in patients with type 2 diabetes: A systematic review and meta-analysis.","authors":"Chunbian Tang, Jiayi Hao, Fengran Tao, Qingguo Feng, Ying Song, Baoqi Zeng","doi":"10.1111/dom.16192","DOIUrl":"https://doi.org/10.1111/dom.16192","url":null,"abstract":"Aim: There is ongoing debate concerning the association of metformin with the risk of dementia in type 2 diabetes mellitus (T2DM). This study was conducted to evaluate the impact of metformin therapy on dementia in patients with T2DM.Materials and methods: PubMed, Embase, Cochrane Library, Web of Science and the ClinicalTrials.gov website were searched until 9 April 2024. Cohort studies investigating the effects of metformin therapy compared with other antidiabetic drugs or no therapy in T2DM were included. The hazard ratio (HR) and the 95% confidence interval (CI) were computed using the random effects model.Results: Twenty cohort studies (24 individual comparisons) involving 3 463 100 participants were identified. A meta-analysis revealed that people with T2DM who take metformin are linked to a lower incidence of all-cause dementia compared to non-user (n = 17, HR = 0.76, 95% CI = 0.65-0.91, p = 0.002, I2 = 98.9%) and sulfonylureas (n = 5, HR = 0.88, 95% CI = 0.85-0.90, p < 0.001, I2 = 9.7%), but not to thiazolidinedione (n = 2, HR = 0.53, 95% CI = 0.08-3.41, p = 0.503, I2 = 92.7%). Additionally, metformin showed favourable effects in non-specified T2DM (n = 19, HR = 0.75, 95% CI = 0.64-0.89), but not in newly diagnosed T2DM (n = 5, HR = 1.01, 95% CI = 0.81-1.27).Conclusion: Metformin might correlate with a lower dementia incidence in people with T2DM. However, it is crucial to interpret these results with caution considering the high heterogeneity.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A preliminary randomized trial of a brief dissonance-based type 2 diabetes prevention programme for adults with pre-diabetes. 一项针对糖尿病前期成人的基于失调的2型糖尿病预防方案的初步随机试验。

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-07 DOI: 10.1111/dom.16170

Eric Stice, Paul Rohde, Christopher D Desjardins, Kristen Gee, Heather Shaw, Sun Kim

{"title":"A preliminary randomized trial of a brief dissonance-based type 2 diabetes prevention programme for adults with pre-diabetes.","authors":"Eric Stice, Paul Rohde, Christopher D Desjardins, Kristen Gee, Heather Shaw, Sun Kim","doi":"10.1111/dom.16170","DOIUrl":"https://doi.org/10.1111/dom.16170","url":null,"abstract":"Objective: Conduct a preliminary randomized trial that compared a 6-week type 2 diabetes (T2D) prevention programme to an educational video control for adults with pre-diabetes.Methods: Adults (N = 62) with pre-diabetes were randomized to the group-delivered Project Health T2D or an educational video control, completing measures at pre-test, post-test and 3-month follow-up.Results: Participants randomized to the intervention versus control condition showed significantly greater reductions in body fat (d = 0.76, p = 0.002; d = 1.07, p < 0.001), weight (d = 0.59, p = 0.030; 0.65, p = 0.017) and body mass index (BMI = kg/m2; d = 0.60, p = 0.030; 0.67, p = 0.014), significantly greater increases in lean mass (d = 0.80, p = 0.003; 0.93, p = 0.001) at post-test and 3-month follow-up, respectively, and marginally greater reductions in glycated haemoglobin (HbA1c) (d = 0.54, p = 0.056), but not fasting plasma glucose at 3-month follow-up (d = 0.25, p = 0.364). Project Health T2D also produced a marginally greater 75% reduction in future onset of type 2 diabetes compared with educational controls, reducing incidence over the total 5-month observation period from 15% to 4% (odds ratio = 4.52, p = 0.096).Conclusions: Project Health T2D produced encouraging reductions in body fat, weight and T2D incidence, and increases in lean mass, and is less intensive than other lifestyle modification T2D prevention programme, suggesting that it might be useful to evaluate in a fully powered efficacy trial with a longer follow-up.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

MicroRNA-mediated Ets1 repression in retinal endothelial cells: A novel anti-angiogenic mechanism in nonproliferative diabetic retinopathy. 视网膜内皮细胞中微rna介导的Ets1抑制：非增生性糖尿病视网膜病变中一种新的抗血管生成机制。

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-07 DOI: 10.1111/dom.16182

Jianyu Zhao, Zewen Sun, Zimeng Li, Mengyu Xu, Aowen Tian, Zhengwen An, Wenbo Guo, Chang He, Ying Dong, Jianping Wen, Jianli Yang, Qing Wang, Peng Chen

{"title":"MicroRNA-mediated Ets1 repression in retinal endothelial cells: A novel anti-angiogenic mechanism in nonproliferative diabetic retinopathy.","authors":"Jianyu Zhao, Zewen Sun, Zimeng Li, Mengyu Xu, Aowen Tian, Zhengwen An, Wenbo Guo, Chang He, Ying Dong, Jianping Wen, Jianli Yang, Qing Wang, Peng Chen","doi":"10.1111/dom.16182","DOIUrl":"https://doi.org/10.1111/dom.16182","url":null,"abstract":"Aims: This study aimed to discover the regulatory mechanisms contributing to angiogenesis in nonproliferative diabetic retinopathy (NPDR).Materials and methods: This study employed a case-control design involving type 2 diabetes patients with and without NPDR. We utilised microRNA sequencing to analyse plasma and retina samples from T2D patients, to identify both existing and novel microRNAs relevant to retinal health. An integrative approach combining single-cell sequencing data from mouse and rat models was used to explore the molecular mechanism in retinal cells under diabetes condition.Results: We identified a specific set of circulating microRNAs with strong predictive potential for distinguishing NPDR patients. In addition, a novel microRNA targeting the ETS proto-oncogene 1 (Ets1), a key regulator of microvascular angiogenesis, was found to be upregulated in the plasma of NPDR patients. Analysis of single-cell sequencing data suggested that Ets1 expression was downregulated in diabetic endothelial cells and was associated with the repression of Angiopoietin-1 and phosphoinositide 3-kinase-Akt (PI3K-Akt) signalling pathways, indicating an anti-angiogenic mechanism in NPDR.Conclusions: The identification of a novel microRNA involved in the anti-angiogenic mechanism in NPDR provides new insights into the molecular underpinnings of endothelial dysfunction in diabetic retinopathy. Our retina-specific circulating microRNA panel has potential utility in risk assessment and early detection of NPDR.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial. 实时连续血糖监测改善2型糖尿病冠状动脉搭桥术患者术后血糖控制：一项随机临床试验

IF 5.4 2区医学

Diabetes, Obesity & Metabolism Pub Date : 2025-01-07 DOI: 10.1111/dom.16177

Heejun Son, Suk Ho Sohn, Hyun Ah Kim, Hun Jee Choe, Hyunsuk Lee, Hye Seung Jung, Young Min Cho, Kyong Soo Park, Ho Young Hwang, Soo Heon Kwak

{"title":"Real-time continuous glucose monitoring improves postoperative glucose control in people with type 2 diabetes mellitus undergoing coronary artery bypass grafting: A randomized clinical trial.","authors":"Heejun Son, Suk Ho Sohn, Hyun Ah Kim, Hun Jee Choe, Hyunsuk Lee, Hye Seung Jung, Young Min Cho, Kyong Soo Park, Ho Young Hwang, Soo Heon Kwak","doi":"10.1111/dom.16177","DOIUrl":"https://doi.org/10.1111/dom.16177","url":null,"abstract":"Background: Effective glycaemic control following cardiac surgery improves clinical outcomes, and continuous glucose monitoring (CGM) might be a valuable tool in achieving this objective. We investigated the effect of real-time CGM and telemonitoring on postoperative glycaemic control in people with type 2 diabetes (T2D) after coronary artery bypass grafting (CABG).Methods: In this randomized clinical trial (RCT), adults with T2D undergoing CABG were assigned to either a test group utilizing real-time CGM (Dexcom G6) and telemetry for glycaemic control, or a control group with blinded CGM measures, relying on point-of-care measures. The primary outcome was the percentage of time in range (TIR) of blood glucose between 70 and 180 mg/dL (3.9-10.0 mmol/L), measured by CGM.Results: Among 91 subjects, 48 were in the test group and 43 were in the control group. The least squares (LS) mean ± standard error of TIR was 60.3 ± 2.7%, 50.3 ± 2.9% in the test and control group, respectively. The test group had significantly higher TIR when adjusted with age, sex, body mass index, baseline fasting blood glucose and baseline glycated haemoglobin (LS mean difference, 10.0%; 95% confidence interval, 2.1-18.0; p = 0.014). The test group also had lower time above range and mean glucose levels, with no differences in time below range or hypoglycaemic events.Conclusions: In this RCT, real-time CGM and telemonitoring improved glycaemic control during postoperative period without increasing hypoglycaemia risk. Given the benefits of effective glycaemic control on perioperative outcomes, CGM may be helpful in managing T2D after CABG.","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142941558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0